Back to News
Market Impact: 0.3
IRIDEX Q2 Loss Widens Y/Y as Retina Weakness Weighs, Stock Down 15%
Source: zacks.com
Company FundamentalsCorporate EarningsConsumer Demand & Retail
IRIX reported a Q2 loss per share that widened year over year while revenue declined, as Middle East disruptions and weaker sell-through in China weighed on retina sales. Cyclo G6 continued to grow, but the product-family gains were not enough to offset declines in the core retina segment.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
IRIX-0.55
More News
- Brian Sullivan: Why the 'real' price of oil is likely $30-$40 higher than where it is now
- CoreWeave credit default swaps hit distress levels as investors sour on AI debt
- Penske Automotive agrees to be taken private by Penske, Mitsui
- Supermicro promised a new CFO in December 2024. A $2.5 billion smuggling case and a co-founder’s arrest later, it has one
- Blackstone President Jon Gray Bets Big on AI Boom
- What's behind the sell-off in AI neocloud stocks like CoreWeave and Nebius